NCT05729607

Vertical Soft Tissue Augmentation With CTG vs ADM

Vertical Soft Tissue Augmentation With Dermal Matrix and Enamel Matrix Derivative vs Connective Tissue Graft for the Treatment of Peri-implant Soft Tissue Dehiscences in the Esthetic Zone: A Randomized, Controlled, Clinical, Trial

• Status: Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 28 (estimated)
• Sponsor: Harvard Medical School (HMS and HSDM) · Academic / Other
• Sex: All
• Age: 18 Years – 99 Years
• Healthy volunteers: Accepted

Summary

The study aims at comparing two different approaches for vertical soft tissue augmentation at implant sites exhibiting soft tissue dehiscences: autogenous connective tissue graft vs acellular dermal matrix + enamel matrix derivative

Detailed description

The present randomized clinical trial aims at investigating two approaches (autogenous connective tissue graft vs acellular dermal matrix + enamel matrix derivative) when performed for vertical soft tissue augmentation at sites with peri-implant soft tissue dehiscences. Clinical, volumetric, ultrasonographic, and patient-reported outcomes will be evaluated at different time points up to 1 year.

Conditions

• Implant Complication

Interventions

Type	Name	Description
PROCEDURE	Vertical soft tissue augmentation	Vertical soft tissue augmentation with autogenous connective tissue graft (CTG)
PROCEDURE	Vertical soft tissue augmentation	Vertical soft tissue augmentation with acellular dermal matrix (ADM) and enamel matrix derivative (EMD)

Timeline

• Start date: 2023-05-26
• Primary completion: 2027-02-27
• Completion: 2027-11-27
• First posted: 2023-02-15
• Last updated: 2025-09-18

Locations

1 site across 1 country: United States